Tandem Diabetes Care Inc. (TNDM)
TNDM trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1438133/000143813326000010/0001438133-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TNDM on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001438133 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.0B |
| Net income | -$204.7M |
| Operating income | -$187.3M |
| Net margin | -20.2% |
| Operating margin | -18.5% |
| Revenue growth | +7.9% |
| Cash | $90.6M |
| Total assets | $881.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $72.8M cash; operating cash flow -$3.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 69,793,846 (2026-11-02); 67,802,359 a year earlier; 65,209,703 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $283.7M | -$7.1M | -$819K | $72.8M | $603.4M | $1.1B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $254.6M | -$21.2M | -$34.6M | $62.8M | $602.6M | $1.0B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $247.2M | -$20.4M | $11.1M | $179.3M | $601.8M | $1.0B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $290.4M | -$589K | $9.8M | $90.6M | $310.0M | $1.0B | 10-K 2026-02-19 |
| Q3 2025 2025-09-30 | $249.3M | -$21.2M | $8.3M | $91.9M | $309.6M | $1.0B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $240.7M | -$52.4M | -$9.5M | $64.1M | $309.1M | $1.0B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $234.4M | -$130.6M | -$18.3M | $53.6M | $308.7M | $983.0M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $282.6M | $755K | $10.7M | $69.2M | $348.9M | $940.2M | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document 424B5 PROSPECTUS 08-2018 | 424B5 | 2018-08-03 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-07 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +18.7% |
| 1 month | +20.5% |
| 3 months | -13.2% |
| Year to date | -8.7% |
| 1 year | +14.5% |
| From 52-week high | -29.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVCR | NovoCure Limited | $11.30 | -4.48% | $1.3B |
| PRCT | PROCEPT BioRobotics Corporation | $23.54 | -1.09% | $1.4B |
| DRTS | Alpha Tau Medical Ltd. | $11.97 | -10.54% | $1.1B |
| IART | Integra LifeSciences Holdings Corporation | $13.98 | -2.92% | $1.1B |
| IRMD | iRadimed Corporation | $84.84 | -0.60% | $1.1B |
| SGP | SpyGlass Pharma Inc. | $32.24 | -1.95% | $1.1B |
| SIBN | SI-BONE Inc. | $23.41 | -0.13% | $1.1B |
| ATEC | Alphatec Holdings Inc. | $6.78 | -4.10% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier